← Leaderboards
Thomas Alan Hamilton
Cleveland Clinic Foundation
$9,156,541
Attributed
$9,513,166
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $897.6K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$9,513,166 · 8
By mechanism
R01$5,971,885 · 3
P01$3,541,281 · 5
Top collaborators
- Feng Lin2 shared
Most similar at Cleveland Clinic Foundation
Same institution · by research overlap
- Thomas Weimbs$9,566,724
- Saikh J Haque$3,016,656
Others in their field
Top investigators on “Macrophage”
- Craig B Thompson · Sloan-Kettering Inst Can Research$41,669,179
- Howard Eliot Gendelman · Children'S Memorial Hospital (Chicago)$41,668,744
- Selwyn M Vickers · University Of Alabama At Birmingham$40,969,055
- Alan A Aderem · University Of Washington$38,969,733
- Alan Richard Tall · Columbia University Health Sciences$38,053,695
- John S Condeelis · Yeshiva University$33,855,255
Research focus
MacrophageInflammationLaboratory MouseGene ExpressionImmuneInflammatoryDesignPathway InteractionsMessenger RnaTumorProtein Protein InteractionChemokineCellsCytokineResponseLeukocyte Activation /TransformationMediatingTissue /Cell CultureGenesSignal TransductionInterferon GammaMalignant NeoplasmsGenetic TranscriptionBase Sequence
Grant awards (34)
Core B: Animal Model and Immunotyping Core$372,966
P01 · FY2024 · CA · contact PI
IL-17-driven mechanisms for tumor progression and resistance to therapies$512,644
P01 · FY2023 · CA · contact PI
Core B: Animal Model and Immunotyping Core$384,934
P01 · FY2023 · CA · contact PI
Local inhibition of complement to improve MSC-based therapy for diabetes$356,625
R01 · FY2018 · DK
Local inhibition of complement to improve MSC-based therapy for diabetes$356,625
R01 · FY2017 · DK
Post-transcriptional control of inflammatory gene expression$270,687
R01 · FY2013 · CA · contact PI
Post-transcriptional control of inflammatory gene expression$287,965
R01 · FY2012 · CA · contact PI
Post-transcriptional control of inflammatory gene expression$287,965
R01 · FY2011 · CA · contact PI
Post-transcriptional control of inflammatory gene expression$296,871
R01 · FY2010 · CA · contact PI
STAT6 and IL-4/IL-13 Dependent Gene Expression$339,700
P01 · FY2009 · CA · contact PI
Post-transcriptional control of inflammatory gene expression$296,871
R01 · FY2009 · CA · contact PI
STAT6 and IL-4/IL-13 Dependent Gene Expression$332,112
P01 · FY2008 · CA · contact PI
STAT6 and IL-4/IL-13 Dependent Gene Expression$331,190
P01 · FY2007 · CA · contact PI
Mechanisms of Macrophage Activation$280,880
R01 · FY2007 · CA · contact PI
Regulation of Chemokine Expression In Vivo$336,161
R01 · FY2006 · AI · contact PI
Mechanisms of Macrophage Activation$280,880
R01 · FY2006 · CA · contact PI
STAT6 and IL-4/IL-13 Dependent Gene Expression$216,776
P01 · FY2006 · CA · contact PI
Regulation of Chemokine Expression In Vivo$344,250
R01 · FY2005 · AI
Mechanisms of Macrophage Activation$287,640
R01 · FY2005 · CA
STAT6 and IL-4/IL-13 Dependent Gene Expression$210,722
P01 · FY2005 · CA
Regulation of Chemokine Expression In Vivo$344,250
R01 · FY2004 · AI
Mechanisms of Macrophage Activation$287,640
R01 · FY2004 · CA
Regulation of Chemokine Expression In Vivo$333,000
R01 · FY2003 · AI
Mechanisms of Macrophage Activation$287,640
R01 · FY2003 · CA
Regulation of Chemokine Expression In Vivo$333,000
R01 · FY2002 · AI
MECHANISMS OF MACROPHAGE ACTIVATION$239,797
R01 · FY2002 · CA
ANTIINFLAMMATORY MECHANISMS OF INTERLEUKIN 4$91,598
P01 · FY2002 · CA
CORE--TISSUE CULTURE$91,598
P01 · FY2002 · CA
MECHANISMS OF MACROPHAGE ACTIVATION$234,258
R01 · FY2001 · CA
CORE--TISSUE CULTURE$91,598
P01 · FY2001 · CA
ANTIINFLAMMATORY MECHANISMS OF INTERLEUKIN 4$91,598
P01 · FY2001 · CA
ANTIINFLAMMATORY MECHANISMS OF INTERLEUKIN 4$236,924
P01 · FY2000 · CA
CORE--TISSUE CULTURE$236,921
P01 · FY2000 · CA
MECHANISMS OF MACROPHAGE ACTIVATION$228,880
R01 · FY2000 · CA